Stocks · News reference
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $582 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Praxis Precision Medicines, Inc. announced it will report its third quarter 2026 financial results on November 9, 2026, and will host an Investor Day on November 12, 2026.
Praxis Precision Medicines is recognized as a 'Shine Sponsor' for the 2026 International LGS Awareness Day, supporting the foundation's mission to improve the lives of those affected by LGS.
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.